p53 protein expression in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1282-1288

  Sellmann, Ludger ^a   Carpinteiro, Alexander ^a   Nückel, Holger ^a   Scholtysik, René ^a   Siemer, Dörte ^a   Klein Hipass, Ludger ^a   Kube, Dieter ^b   Dürig, Jan ^a   Dührsen, Ulrich ^a   Stanelle, Jens ^a   Küppers, Ralf ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

CLL; FISH; p53 ; p53 ; p53 protein expression

Indexed keywords

P53 BETA PROTEIN; P53 GAMMA PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOTTING, WESTERN; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862739788     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654115     Document Type: Article

References (39)

1. Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006;33:186-194.
2. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-861. (Pubitemid 43156279)
3. Gunnarsson R, Staaf J, Jansson M, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia - a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008;47:697-711. (Pubitemid 351847582)
4. Döhner H, Stilgenbauer S, Fischer K, et al. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997;11(Suppl. 2):S19-S24.
5. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529. (Pubitemid 35403967)
6. Stilgenbauer S, Döhner H. Genotypic prognostic markers. Curr Top Microbiol Immunol 2005;294:147-164. (Pubitemid 41491254)
7. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389-1401.
8. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
9. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009;114:5307-5314.
10. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
11. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287-295. (Pubitemid 36560596)
12. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004;5:47-54. (Pubitemid 38262790)
13. Van Den NE, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007;21:1715-1722. (Pubitemid 47086762)
14. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008;111:1584-1593. (Pubitemid 351213449)
15. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
16. Zenz T, Benner A, Dohner H, et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810-3814.
17. Chang H, Jiang AM, Qi CX. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. Am J Clin Pathol 2010;133:70-74.
18. Marinelli M, Raponi S, Del Giudice I, et al. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia? Am J Clin Pathol 2011;135:173-174.
19. Olivares-Illana V, Fahraeus R. p53 isoforms gain functions. Oncogene 2010;29:5113-5119.
20. Bourdon JC. p53 and its isoforms in cancer. Br J Cancer 2007;97:277-282.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group guidelines. Blood 2008;111:5446-5456.
22. Nückel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C > A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109:290-297. (Pubitemid 46053069)
23. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
24. Sellmann L, Scholtysik R, Kreuz M, et al. Gene dosage effects in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2010;203:149-160.
25. Feuerborn A, Moritz C, Von BF, et al. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1932-1940. (Pubitemid 44649780)
26. Nückel H, Hüttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1053-1061. (Pubitemid 44102969)
27. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005;19:2122-2137. (Pubitemid 41330315)
28. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
29. Stilgenbauer S, Lichter P, Döhner H. Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:48-72. (Pubitemid 34947478)
30. Zenz T, Mertens D, Küppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
31. Graupner V, Schulze-Osthoff K, Essmann F, et al. Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 2009;8:1238-1248.
32. Anensen N, Oyan AM, Bourdon JC, et al. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006;12:3985-3992. (Pubitemid 44078084)
33. Boldrup L, Bourdon JC, Coates PJ, et al. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 2007;43:617-623. (Pubitemid 46177591)
34. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009;11:1135-1142.
35. Christodoulopoulos G, Fotouhi N, Krajewski S, et al. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X and p53. Cancer Lett 1997;121:59-67. (Pubitemid 27504315)
36. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005;65:9152-9154. (Pubitemid 41507976)
37. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005;65:375-378.
38. Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005;65:8597-8603. (Pubitemid 41377342)
39. Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 2005;65:8597-8603. (Pubitemid 41377342)